Ondine Biomedical Inc. Share Price

Equities

OBI

CA68234M2058

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 16:35:20 12/06/2024 BST 5-day change 1st Jan Change
7.5 GBX 0.00% Intraday chart for Ondine Biomedical Inc. -9.09% -14.29%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 1.2M 875K 68.48M Sales 2024 * 2.5M 1.82M 142M Capitalization 36.56M 26.61M 2.08B
Net income 2023 -14M -10.19M -797M Net income 2024 * -18M -13.1M -1.02B EV / Sales 2023 27.8 x
Net cash position 2023 * 1.1M 800K 62.62M Net cash position 2024 * 3.8M 2.77M 216M EV / Sales 2024 * 13.1 x
P/E ratio 2023
-2.19 x
P/E ratio 2024 *
-2.59 x
Employees 18
Yield 2023 *
-
Yield 2024 *
-
Free-Float 28.97%
More Fundamentals * Assessed data
Dynamic Chart
1 week-9.09%
Current month+7.14%
1 month+7.14%
3 months-18.92%
6 months-16.67%
Current year-14.29%
More quotes
1 week
7.00
Extreme 7
8.32
1 month
6.50
Extreme 6.5
8.50
Current year
5.00
Extreme 5
11.40
1 year
5.00
Extreme 5
17.00
3 years
5.00
Extreme 5
60.00
5 years
5.00
Extreme 5
60.00
10 years
5.00
Extreme 5
60.00
More quotes
Managers TitleAgeSince
Founder 62 08/09/96
President 64 29/02/04
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 58 06/12/21
Founder 62 08/09/96
President 64 29/02/04
More insiders
Date Price Change Volume
12/06/24 7.5 0.00% 65,800
11/06/24 7.5 +3.45% 170,076
10/06/24 7.25 0.00% 14,157
07/06/24 7.25 -12.12% 591,525
06/06/24 8.25 0.00% 126,773

Delayed Quote London S.E., June 12, 2024 at 04:35 pm

More quotes
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.075 GBP
Average target price
0.55 GBP
Spread / Average Target
+633.33%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW